

Patterns of Drug Prescription among Rheumatoid Arthritis Patients in King Hussien Medical City (KHMC)

Ekbal N.Thuhairat, MSc.Pharm^{1*}, Belal Al-Husein, PhD², Muhammd AL-Uleamat MSc.Pharm³, Anmar N. Daherat RN⁴, Muhammad Jarere BSc Pharm⁵

¹Lt. Col Pharmacist, Departments of Pharmacy, Royal Medical Services, Amman, Jordan

²Assistant Professor of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid Jordan

³Majer Pharmacist, Departments of Pharmacy, Royal Medical Services, Amman, Jordan

⁴1st. Lt RN, Royal Medical Services, Amman, Jordan

⁵1st. Lt Pharmacist, Departments of Pharmacy, Royal Medical Services, Amman, Jordan

*Corresponding author: Ekbal N. Thuhairat

| Received: 15.05.2019 | Accepted: 22.05.2019 | Published: 30.05.2019

DOI: [10.36347/sjams.2019.v07i05.033](https://doi.org/10.36347/sjams.2019.v07i05.033)

Abstract

Original Research Article

Aim: This study was carried out in order to report the prescribing pattern of drugs used in the treatment of Rheumatoid Arthritis (RA) among Jordanian patients who receive their medical care at Royal Rehabilitation Center in Royal Medical Services (RRC/RMS) Amman/Jordan during the period from October 2013 to March 2014, in addition, we evaluated if the pattern of prescriptions of disease-modifying anti-rheumatic drugs (DMARDs) used is rational and was it in accordance with international guidelines for management of RA.

Methodology: A retrospective cross sectional study was conducted in the out-patient pharmacy of the RRC/RMS. RRC is a tertiary care hospital which receives RA referrals from other clinics and hospitals; it covers 15 rheumatology subspecialty clinics weekly and is directed through specialist and consultant physicians. Inclusion criteria include all the prescriptions with the diagnosis of RA that were dispensed from the pharmacy during the period of October 1st 2013 till March 31st, 2014, or any prescription that contain at least one DMARD for patients whom ages are ≥ 18 years. These prescriptions were studied and analyzed for the number of drugs in the prescription, name of the drug, dose, and frequency. The demographic profile of the patients regarding age and sex was also obtained from the prescription. Statistical analysis was performed using the statistical package for social science SPSS version 17. The study had been ethically approved from the ethical committee in the Directorate of Royal Medical Services. **Results:** There were a total of 800 prescriptions for DMARDs during the study period, 557 were female patients and 243 were for male (F: M ratio =2.3:1) with ages ranging from 18-82 year (mean 49.2 ± 5.8 year). The distribution of age was such that the highest percentages (46.3%) of patient were between the age group of 40-60 followed by 38.5% above 60 years. The overall average number of drugs per prescription was 6.41 ranging from 1-8 drugs. All the patients included in the study were prescribed DMARDs either alone or in combination, the percentage of prescriptions with DMARDs monotherapy and combination therapy was 28% and 72%, respectively. Almost most of combination therapies (77%) were prescribed two DMARDs while only 23% were given 3 DMARDs. It was found that methotrexate was prescribed for 96% of the prescriptions (25% as monotherapy, 30% with salazopyrine, 25% with hydroxychloroquine and 16% with both salazopyrine and hydroxychloroquine). **Conclusion:** Our study represents the current pattern of drug prescribing among RA patients in a tertiary care hospital. It is obvious that the leading drug for treatment of RA is methotrexate either alone or in combination, also it was found that treatment with combination therapy were more common than monotherapy in most RA patients and those practices is in accordance with the current recommendations and guidelines. Management of RA is continuously changing and new drugs are being added, our study constitutes a baseline data, extra studies could give more insights about the prescribing practice of the clinician.

Key words: Rheumatoid Arthritis; DMARDs; combination therapy.

Copyright © 2019: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of unknown cause,

chiefly affecting synovial membranes of multiple joints. RA has a high prevalence and approximately affects 1-2% of the general population worldwide [1]. The disease has a wide clinical and extra-articular manifestations

and it is an established risk factor for many complications that affect the quality of life [2, 3].

Many treatment protocols and algorithms have been used for the management of RA. Protocols are mainly based on a group of drugs known as disease-modifying anti-rheumatic drugs (DMARDs). They had improved control of disease activity, slowed down joint erosions and improved the quality of life as well as reduced associated cardiovascular-morbidity; such as ischemic heart disease [4, 5, and 6]. Immediate and aggressive DMARDs therapy is recommended now by most current treatment approaches and algorithms. DMARDs also represent the standard of care for RA in the recent clinical practice. Currently, more than 90% of RA patients are treated with DMARDs in the major rheumatologic societies, and in rheumatic disease specialty practices [7-9],

An effective method to study and evaluate the prescribing pattern of the physicians and drug dispensing attitude of pharmacists is through conducting a survey based on prescriptions review. Studying the prescribing pattern is a component of medical audit which is necessary to determine areas that require improvements and corrections in order to provide rational and cost effective medical care.

This study was carried out in order to report the prescribing pattern of drugs used in the treatment of RA among Jordanian patients who receive their medical care at RRC/ RMS during the period from October 2013 to March 2014, in addition, we evaluated if the pattern of prescriptions of DMARDs used is rational and was it in accordance with international guidelines for management of RA.

METHODOLOGY

A retrospective cross sectional study was conducted in the out-patient pharmacy of the RRC/RMS. RRC is a tertiary care hospital which receives RA referrals from other clinics and hospitals; it covers 15 rheumatology subspecialty clinics weekly and is directed through specialist and consultant physicians.

Inclusion criteria include all the prescriptions with the diagnosis of RA that were dispensed from the pharmacy during the period of October 1st 2013 till March 31st, 2014, or any prescription that contain at least one DMARD for patients whom ages are ≥ 18 years. These prescriptions were studied and analyzed for the number of drugs in the prescription, name of the drug, dose, and frequency. The demographic profile of the patients regarding age and sex was also obtained from the prescription.

Statistical analysis was performed using the statistical package for social science SPSS version 17. The study had been ethically approved from the ethical committee in the Directorate of Royal Medical Services.

RESULTS

There were a total of 800 prescriptions for DMARDs during the study period, 557 were female patients and 243 were for male (F: M ratio =2.3:1) with ages ranging from 18-82 year (mean 49.2 ± 5.8 year). The distribution of age was such that the highest percentages (46.3%) of patient were between the age group of 40-60 followed by 38.5% above 60 years. The demographics of the study group are presented in table (1). The overall average number of drugs per prescription was 6.41 ranging from 1-8 drugs.

Table-1: Demographic Characteristics of the study group (N=800)

Patient Characteristics		Males N = 243	Females N=557	Total patients N=800
Age group (years)	18-40	21	101	122
	40-60	141	229	370
	≥ 60	81	227	308
Mean age (years)		50.7	49.8	50.25
Average number of drugs per prescription		6.41	7.32	6.87

Figure (1) reveals the prescribing pattern for the RA patients in the study. The majority of them (92%) were prescribed non-steroidal anti-inflammatory drugs (NSAIDs) on regular frequency or when required.

About one-fourth (26%) of all RA patients were prescribed prednisolone tablet usually in a daily dose of 5-12.5mg.




Fig-1: Prescribing pattern of medications. NSAIDs: Non-steroidal anti-inflammatory drugs

All the patients included in the study were prescribed DMARDs either alone or in combination, the percentage of prescriptions with DMARDs monotherapy and combination therapy was 28% and 72%, respectively. Almost most of combination

therapies (77%) were prescribed two DMARDs while only 23% were given 3 DMARDs. The prescribing patterns for DMARDs therapy for the treatment of RA patients in this study is presented in Figure (2).




Fig-2: The prescribing pattern for DMARDs therapy

Figure (3) is a breakdown for various DMARDs prescription patterns among RA patients. It was found that methotrexate was prescribed in 25% of the total patients as monotherapy while salazopyrine and hydroxychloroquine were given to 3% and 2% of the total patients respectively.

Concerning patients who were on two DMARDs, our study revealed that 375 (56%) of the total patients were on two drugs. Methotrexate was the leading drug in combination therapy (55%) of the total

patients. The most frequently used combination were methotrexate and salazopyrine (30%) of the total patients, followed by methotrexate and hydroxychloroquine (25%). Patients who were on three DMARDs therapy constitute (16%) from total patients, all of them were on methotrexate, hydroxychloroquine and salazopyrine. Although the biologic DMARDs are available in the drug formulary of the RMS but there wasn't any prescription for them during the six months of the study period.




Fig-3: Breakdown for various DMARDs prescription pattern. MTX: methotrexate, SAZ: salazopyrine, HCQ: hydroxychloroquine

Analyzing the prescribing patterns among our RA patients reveals that additional drug therapy was

also co-prescribed along with DMARDs as shown in Figure (4).




Fig-4: Additional medications prescribed for RA patients

About one third of the patients (37%) were prescribed concomitantly an analgesic (the widely used analgesic agent was paracetamol). A significant proportion (83%) of the patients was treated with a gastroprotective agent either a proton pump inhibitor such as omeprazole or H2 –blocker such as famotidine. Calcium salts and vitamin D derivatives were also co-prescribed to a large number of patients (81%), bisphosphonates and iron supplementation were also given to 66% and 76% of the patients respectively. All of the methotrexate patients received a folic acid supplementation usually in a dose of 5mg twice weekly maintenance therapy.

DISCUSSION

According to the Current treatment paradigms in RA, early aggressive and persistent use of DMARDs should be followed to prevent joint destruction and long-term physical disability in those patients [9].

There is widespread acceptance and many evidence based clinical guidelines recommendations

about early referral to a specialist rheumatologist when a diagnosis of RA is suspected, for definitive diagnosis and early introduction of DMARDs and continued follow-up of a rheumatologist to assess response to treatment and review the treatment plan [4, 5, 8, 12-14].

All of the prescriptions that were prescribed to our patients in our study contain at least one DMARD this fellow the recommended guidelines. In this study, it is notable that methotrexate was the most commonly prescribed drug for RA (96%) either alone (25%) or in combination therapy (71%) followed by salazopyrine (49%) and hydroxychloroquine (45%) either alone or in combination therapy. For many decades methotrexate was the most commonly used DMARDs as a single agent or in multidrug therapy, its disease modifying quality and tolerability account for long duration of therapy [15-17]. Our result is similar to other recent studies about rheumatologist prescribing patterns and other recommendation that methotrxate has an established efficacy in rheumatoid arthritis and it is still considered as the main drug for treating RA, showing

the superiority over hydroxychloroquine and salazopyrine [18-22].

Our study revealed that combination therapy using two DMARDs or more (72%) was more common than monotherapy (28%), this result is also indicating that the prescribers are following the guidelines recommendation for treating RA which recommend that early diagnosis of RA prompted the use of DMARDs in higher doses and often in combination therapy to control the disease activity and this result is supported by other studies that showed that RA could be adequately controlled with the use of combination therapy, furthermore multiple drug therapy seems to be a rational approach in the management of RA to decrease the mortality.

The demographic characteristics of our study group is in agreement with the current epidemiological concepts regarding age and sex prevalence in RA since RA is one of many chronic inflammatory diseases that affect female gender more frequently than male with an age of onset at middle age . In our study there was a higher female predominance (69.6%) (2.3 times greater in females than in males) and the highest percentage of patients 46.3% were in the middle age group of (between the age group of 40-60 year) [23, 24].

The prescription trend in our study reveals the pattern of polypharmacy. the average number of drugs per prescription was found to be 6.41, that is above the recommendations of the WHO which has recommended that the limit of number of drugs prescribed per prescription should be two and that justification for prescribing more than two drugs would be required because of the increased risk of drug interactions that increases the likely hood of nonadherence with the medication prescribed, but in patients with RA polypharmacy is a common practice since those patients often have a greater number of co morbidities with associated disability and complex medication regimens [25-27].

The noted polypharmacy obvious in our study (63% of the prescriptions contains 5 drugs or more) may be attributed to the adherence of most clinician to the guidelines of RA management since that some patients need their disease to be more controlled by using more than one DMARDs, also other medications like NSAIDs and analgesics are co prescribed to those patients for more control of the pain associated with disease, as the control of pain is an important aim in the management of RA. Gastroprotective agents are also co prescribed with DMARDs to overcome the gastrointestinal side effects associated with the use of these drugs. A high number of patients were concomitantly prescribed folic acid along with methotrexate in order to reduce some of its side effects. Osteoporosis is well recognized among RA patients and prescribing calcium salts, vitamin D derivatives and

bisphosphonates increase the number of drugs that are prescribed concomitantly and give a high incidence of polypharmacy among those patients.

CONCLUSION

Our study represents the current pattern of drug prescribing among RA patients in a tertiary care hospital. It is obvious that the leading drug for treatment of RA is methotrexate either alone or in combination, also it was found that treatment with combination therapy were more common than mono therapy in most RA patients and those practices is in accordance with the current recommendations and guidelines. Management of RA is continuously changing and new drugs are being added, our study constitutes a baseline data, extra studies could give more insights about the prescribing practice of the clinician. It is recommended that regular education for both the clinician on rational use of drugs and also for the patient for more drugs compliance in order to achieve better control of the disease with the lowest possible medication use.

REFERENCES

1. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. *Pharmacoeconomics*. 2004 Sep 1;22(1):1-2.
2. Grijalva CG, Chung CP, Stein CM, Mitchel Jr EF, Griffin MR. Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population. *Rheumatology*. 2008 May 22;47(7):1061-4.
3. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas B, Hansen RA, Morgan LC, Williams SC, Lohr KN. Comparative effectiveness of drug therapy for rheumatoid arthritis and psoriatic arthritis in adults.2007.
4. Fries JF, Williams CA, Morfeld D, Singh G, and Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology*. 1996 Apr;39(4):616-22.
5. Sokka T, Möttönen T, Hannonen P. Disease-modifying anti-rheumatic drug use according to the sawtooth treatment strategy improves the functional outcome in rheumatoid arthritis: Results of a long-term follow-up study with review of the literature. *Rheumatology*. 2000 Jan 1;39(1):34-42.
6. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. *The Lancet*. 2002 Apr 6;359(9313):1173-7.
7. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. *Arthritis & Rheumatism: Official*

- Journal of the American College of Rheumatology. 1984 Aug;27(8):864-72.
8. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. *Annals of Internal Medicine*. 1999 Nov 16;131(10):768-74.
 9. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. *Arthritis & Rheumatism*. 2002 Feb;46(2):328-46.
 10. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. *Annals of the rheumatic diseases*. 2002 Apr 1;61(4):290-7.
 11. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Care & Research: Official Journal of the American College of Rheumatology*. 2008 Jun 15;59(6):762-84.
 12. Fries JF. Current treatment paradigms in rheumatoid arthritis. *Rheumatology*. 2000 Jun 1;39(suppl_1):30-5.
 13. Abu-Shakra M, Toker R, Flusser D, Flusser G, Friger M, Sukenik S, Buskila D. Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease-modifying drugs. *Arthritis & Rheumatism*. 1998 Jul;41(7):1190-5.
 14. Wollheim FA. Approaches to rheumatoid arthritis in 2000. *Current opinion in rheumatology*. 2001 May 1;13(3):193-201.
 15. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. *The Journal of rheumatology*. 1990 Aug;17(8):994-1002.
 16. Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, Cobly JS. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology*. 1992 Feb;35(2):129-37.
 17. Combe B, Landewé R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM, Klareskog L, Machold K. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Annals of the rheumatic diseases*. 2007 Jan 1;66(1):34-45.
 18. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. *Rheumatology*. 2000 Sep 1;39(9):975-81.
 19. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, Wolfe F, Wall B, Anderson L, Gall E, Torretti D. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology*. 1994 Oct;37(10):1492-8.
 20. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, Wolfe F, Wall B, Anderson L, Gall E, Torretti D. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology*. 1994 Oct;37(10):1492-8.
 21. Rau R, Schleusser B, Herborn G, Karger T. Long-term treatment of destructive rheumatoid arthritis with methotrexate. *The Journal of rheumatology*. 1997 Oct;24(10):1881-9.
 22. Montag K, Gingold M, Boers A, Littlejohn G. Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice. *Internal medicine journal*. 2011 Jun 1;41(6):450-5.
 23. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. *Annals of the rheumatic diseases*. 2009 Jul 1;68(7):1100-4.
 24. Goronzy JJ, Weyand CM. Rheumatoid arthritis: epidemiology, pathology, and pathogenesis. *Primer on the rheumatic diseases*. 2001;11.
 25. Hochberg MC. Adult and juvenile rheumatoid arthritis: current epidemiologic concepts. *Epidemiologic reviews*. 1981 Jan 1;3(1):27-44.
 26. World Health Organization. How to investigate drug use in health facilities: selected drug use indicators. Geneva: World Health Organization; 1993.
 27. Filkova M, Mant T, Cope A, Galloway J. E35. Prevalence of polypharmacy in patients with rheumatoid arthritis and association with disease characteristics. 2015.
 28. Treharne GJ, Douglas KM, Iwaszko J, Panoulas VF, Hale ED, Mitton DL, Piper H, Erb N, Kitas GD. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. *Musculoskeletal Care*. 2007 Dec;5(4):175-90.